Australia Orthopedic Biomaterial – Market Size, Growth Rates and Competitive Landscape – Biomaterials, Biotechnology, Healthcare Industries

The Australia Orthopedic Biomaterial – Market Size, Growth Rates and Competitive Landscape Report has been published. It provides updated in 2018 year analysis of industries from Biomaterials, Biotechnology, Healthcare Markets.

This research report provides key market trends, market forecasts and competitive scenario of the orthopedic biomaterial in Australia through 2020.

The product categories covered in this report include:
– Bone Allografts
– Demineralized Bone Material (DBM)
– Bone Graft Substitutes
– Bone Growth Stimulators
– Viscosupplementation

Scope

The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares.
– Highlights and compares key product categories for growth trends and revenue forecast.
– Market size, annualized revenue and unit sales for each product category from 2007 to 2020.
– Cross category comparison – Growth and revenue comparison for product categories, historic and forecast through 2020.
– Market share of companies.
– Average selling price ($) for each product type (2007 to 2020).
– Recent Events and Developments

Why should you buy?
– Build business strategy by identifying the high growth and attractive market categories
– Develop competitive strategy based on competitive landscape
– Design capital investment strategies based on forecasted high potential segments
– Identify potential business partners, acquisition targets and business buyers
– Plan for a new product launch and inventory in advance
– Prepare management and strategic presentations using the market data

Read more and order at Australia Orthopedic Biomaterial – Market Size, Growth Rates and Competitive Landscape

The Essentials of Biostatistics for Physicians, Nurses, and Clinicians – Bioinformatics, Biotechnology, Healthcare Industries

The The Essentials of Biostatistics for Physicians, Nurses, and Clinicians Report has been published. It provides updated in 2018 year analysis of industries from Bioinformatics, Biotechnology, Healthcare Markets.

A fundamental and straightforward guide to using and understanding statistical concepts in medical research

Designed specifically for healthcare practitioners who need to understand basic biostatistics but do not have much time to spare, The Essentials of Biostatistics for Physicians, Nurses, and Clinicians presents important statistical methods used in today′s biomedical research and provides insight on their appropriate application. Rather than provide detailed mathematics for each of these methods, the book emphasizes what healthcare practitioners need to know to interpret and incorporate the latest biomedical research into their practices.

The author draws from his own experience developing and teaching biostatistics courses for physicians and nurses, offering a presentation that is non–technical and accessible. The book begins with a basic introduction to the relationship between biostatistics and medical research, asking the question Why Study Statistics?, while also exploring the significance of statistical methods in medical literature and clinical trials research. Subsequent chapters explore key topics, including:

  • Correlation, regression, and logistic regression

  • Diagnostics

  • Estimating means and proportions

  • Normal distribution and the central limit theorem

  • Sampling from populations

  • Contingency tables

  • Meta–analysis

  • Nonparametric methods

  • Survival analysis

Throughout the book, statistical methods that are often utilized in biomedical research are outlined, including repeated measures analysis of variance, hazard ratios, contingency tables, log rank tests, bioequivalence, cross–over designs, selection bias, and group sequential methods. Exercise sets at the end of each chapter allow readers to test their comprehension of the presented concepts and techniques.

The Essentials of Biostatistics for Physicians, Nurses, and Clinicians is an excellent reference for doctors, nurses, and other practicing clinicians in the fields of medicine, public health, pharmacy, and the life sciences who need to understand and apply statistical methods in their everyday work. It also serves as a suitable supplement for courses on biostatistics at the upper–undergraduate and graduate levels.

Read more and order at The Essentials of Biostatistics for Physicians, Nurses, and Clinicians

France Bone Graft Substitutes Market Through 2021 – Biomaterials, Biotechnology, Healthcare Industries

The France Bone Graft Substitutes Market Through 2021 Report has been published. It provides updated in 2018 year analysis of industries from Biomaterials, Biotechnology, Healthcare Markets.

The market intelligence report provides critical market data for bone graft substitutes and its categories synthetic bone graft substitutes and BMP for the France market. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of company.

The product categories covered in this report include:
– Synthetic Bone Graft Substitutes
– BMP

Scope

The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares.
– Highlights and compares key product categories for growth trends and revenue forecast.
– Market size, annualized revenue and unit sales for each product category from 2007 to 2021.
– Cross category comparison – Growth and revenue comparison for product categories, historic and forecast through 2021.
– Market share of companies.
– Average selling price ($) for each product type (2007 to 2021).
– Recent Events and Developments

Why should you buy?
– Build business strategy by identifying the high growth and attractive market categories
– Develop competitive strategy based on competitive landscape
– Design capital investment strategies based on forecasted high potential segments
– Identify potential business partners, acquisition targets and business buyers
– Plan for a new product launch and inventory in advance
– Prepare management and strategic presentations using the market data

Read more and order at France Bone Graft Substitutes Market Through 2021

Advances in Immunology, Vol 74 – Biotechnology, Healthcare Industries

The Advances in Immunology, Vol 74 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare Markets.

Advances in Immunology presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for future research.

Read more and order at Advances in Immunology, Vol 74

Data Management of Protein Interaction Networks. Wiley Series in Bioinformatics – Bioinformatics, Biotechnology, Healthcare Industries

The Data Management of Protein Interaction Networks. Wiley Series in Bioinformatics Report has been published. It provides updated in 2018 year analysis of industries from Bioinformatics, Biotechnology, Healthcare Markets.

Interactomics: a complete survey from data generation to knowledge extraction

With the increasing use of high–throughput experimental assays, more and more protein interaction databases are becoming available. As a result, computational analysis of protein–to–protein interaction (PPI) data and networks, now known as interactomics, has become an essential tool to determine functionally associated proteins. From wet lab technologies to data management to knowledge extraction, this timely book guides readers through the new science of interactomics, giving them the tools needed to:

  • Generate and store PPI data

  • Analyze PPI data and networks

  • Develop useful applications

The authors have organized the book according to the workflow of interactomics, beginning with data generation and ending with knowledge extraction. Readers will discover how to make full use of all the databases, tools, and techniques currently available for exploiting interactomics data. They′ll learn a broad range of approaches for the management and analysis of protein interaction data, including topological–, database–, data mining–, and ontology–based methods. The fundamental principles underlying each of these methods are presented in detail, alongside their advantages and disadvantages.

Throughout the book, case studies enable readers to discover how interactomics enables researchers to generate, represent, store, analyze, and manage PPI data and networks. Moreover, the authors discuss new and emerging applications developed from interactomics research.

Data Management of Protein Interaction Networks is recommended for all bioinformaticians and protein researchers who want to take full advantage of interactomics software tools and methods in order to enhance their knowledge of biological processes.

Read more and order at Data Management of Protein Interaction Networks. Wiley Series in Bioinformatics

Cell Therapy Manufacturing Market, 2017-2027 – Biotechnology, Genomics, Healthcare Industries

The Cell Therapy Manufacturing Market, 2017-2027 Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Genomics, Healthcare Markets.

The “Cell Therapy Manufacturing Market, 2017-2027” report provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with in-house manufacturing facilities. These therapies are anticipated to emerge as viable alternatives to conventional treatment options.

The scope of this report primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies. In fact, a number of these players have made heavy investments to expand their existing capabilities and establish new facilities for cell therapy products in order to meet the increasing demand.

Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums to accelerate the transition of these therapies from laboratories to clinics. It is important to highlight that companies that offer logistics and operational services have developed systems / tools for safer and quicker delivery of therapies from manufacturing sites to patients; this has been identified as one of the key challenges in the overall development process.

During the course of our study, we identified over 110 organizations that are actively involved in the manufacturing of cell therapies.

In addition to other elements, the study provides information on:

The current status of the market with respect to key players along with information on the location of their manufacturing facilities, scale of production, type of cells manufactured, purpose of production (fulfilling in-house requirements / as a contract service provider) and the type of organization (industry / non-industry).

Most active regions in terms of cell therapy manufacturing with schematic representations of world maps that clearly highlight the global cell therapy manufacturing hubs.

Roadmaps published by different agencies across the globe to provide strategies to advance cell therapy manufacturing.

Elaborate profiles of key players that offer contract manufacturing services (industry and non-industry) or manufacture cell therapies in-house; each profile covers an overview of the company, information on its manufacturing facilities, and recent collaborations.

Partnerships that have taken place in the recent past covering manufacturing and services agreements, agreements specific to technology / instruments / process developments, and mergers and acquisitions.

A discussion on the key enablers of the market and challenges associated with the cell therapy manufacturing process.

Potential future growth of the cell therapy manufacturing market segmented by the type of cell therapy, source of cells (autologous and allogeneic) and purpose of manufacturing (in-house and contract services). For the purposes of our analysis, we took into consideration several parameters that are likely to impact the growth of this market over the next decade; these include the likely increase in number of clinical studies, patient population, anticipated adoption of commercial cell-therapies and expected variation in manufacturing costs.

We have provided an estimate of the size of the market in the short to mid-term and long term for the period 2017 to 2027. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutics and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base, and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth.

Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Tim Oldham (CEO, Cell Therapies), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi), Dr. Gerard J Bos (CEO, CiMaas).

Example Highlights

Overall, we identified over 60 industry players and 50 academic institutes / non-profit organizations that are actively contributing in the field of cell-therapy manufacturing. We came across 68 players that are involved in manufacturing of immunotherapies and 66 players that possess capabilities for manufacturing adult stem cell therapies. Further, 28 organizations have facilities for both immunotherapies and adult stem cell therapies. Within the stem cell therapy market, we identified 15 and 17 organizations that are involved in the manufacturing of ESCs and iPSCs, respectively.

As majority of cell therapy products are in early phase of development, several manufacturers have facilities that meet the clinical scale production requirements. However, some players (31, as per our research) have developed / are developing commercial scale capacity for cell therapy production. Examples include (in alphabetical order) apceth Biopharma, Brammer Bio, Cell and Gene Therapy Catapult, CELLforCURE, Cognate BioServices, EUFETS, Guy's and St Thomas' Facility, Lonza, MaSTherCell, PharmaCell and WuXi AppTec.

Although the current market landscape is dominated by contract manufacturers, some well-established cell therapy developers have set up in-house manufacturing capabilities to support their requirements of cGMP grade cells. Examples include (in alphabetical order) Adaptimmune, Argos Therapeutics, Cell Medica, Cellular Biomedicine Group, Juno Therapeutics, Kite Pharma and SOTIO. In addition, we identified over 10 organizations that manufacture cell-based therapies for their own clinical research as well as offer contract services to other organizations Examples include (in alphabetical order) Amsterdam BioTherapeutics Unit (AmBTU), apceth Biopharma, Children's GMP / GMP facility (St. Jude Children's Research Hospital), Cook Myosite, John Goldmann Centre for Cellular Therapy (Imperial College London), MolMed, and PCT (a Caladrius Company).

North America has the maximum number of cell therapy manufacturing facilities (~ 43%), followed by the EU where ~40% of the global cell therapy manufacturing facilities are located. Specifically, in the EU, maximum number of manufacturing facilities are located in the UK (~44%). Other emerging pockets for cell therapy manufacturing include Australia, China, Japan, Singapore, South Korea and Israel; facilities in these regions primarily cater to the Asia-Pacific markets.

Over 140 collaborations have been inked between cell therapy developers, cell therapy manufacturers and other stakeholders of the industry. The motive behind the partnerships varies; they have been signed for obtaining manufacturing services, gaining access to services related to data management, reagent supply and logistics, upgrading technologies for manufacturing processes, and acquisition of manufacturing facilities.

The near-term demand for manufacturing of cell-based therapies will primarily be driven by clinical candidates. In the longer term, the currently approved therapies and late-stage therapies (that are likely to get commercialized in future) will act as key drivers of the market. Our outlook is highly promising; we expect the market for cell therapy manufacturing to grow at an annualized growth rate of ~42% over the course of next ten years and be worth over USD 4 billion in 2027.

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our report. The summary offers a high level view on the current state of the cell therapy manufacturing market and its likely evolution over the coming decade.

Chapter 3 provides a general introduction to the cell-based therapies and ATMPs, their classification and definitions. It includes a detailed discussion on manufacturing of cell-based therapies, associated challenges, and application of the currently available for cell therapies. The chapter also provides a detailed description on the regulatory landscape for cell therapies.

Chapter 4 identifies the contract service providers / in-house manufacturers that are actively involved in the manufacturing of ATMPs. It provides details on the ATMP manufacturing capabilities of these organizations, specifically focusing on the type of organization, geographic location of their facilities, scale of operation, type of cells manufactured and the purpose of manufacturing (in-house requirement / third party manufacturing). It contains world maps highlighting the geographical locations of cell therapy manufacturing facilities. Further, it discusses the development trends within the overall cell therapy manufacturing landscape.

Chapter 5 provides details on the roadmaps published by different organizations in various geographies, specifically in the US. These roadmaps describe the strategies that are helpful in accelerating the translation from laboratory to clinics.

Chapter 6 contains detailed profiles of in-house manufacturers. Each profile provides a brief overview of the company, its financial performance, details on manufacturing capabilities and facilities, and the relevant collaborations that have been inked over the last few years.

Chapter 7 contains detailed profiles of key industrial contract manufacturers that have clinical and / or commercial scale manufacturing capacities. Each profile provides a brief overview of the company, details on manufacturing capabilities and facilities, and the relevant collaborations that have been inked over the last few years.

Chapter 8 contains detailed profiles of key academic players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on manufacturing capabilities and facilities.

Chapter 9 discusses the role of non-profit organizations in advancing cellular therapies. It provides a list of prominent organizations and profiles of key organizations in different regions. Additionally, the chapter provides information of international / national societies that help in disseminating knowledge about the advancement of these therapies in the community.

Chapter 10 features a comprehensive analysis of the collaborations and partnerships that have been forged between the players in this market. It includes a brief description on the various types of partnership models that are employed by stakeholders in this domain. We have categorized the deals / agreements, which have been captured during our research, into different models and have provided analysis on trend of partnerships over time.

Chapter 11 presents a ten year forecast to highlight the likely growth of the cell therapy manufacturing market. We have segregated the financial opportunity by type of cell therapy (T-cell immunotherapy, cell-based cancer vaccines, stem cell therapies and other ATMPs) and the source of cells (autologous and allogeneic). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 12 provides a SWOT analysis capturing the key elements and factors that are likely to influence the market’s future.

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 14 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in the industry.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Read more and order at Cell Therapy Manufacturing Market, 2017-2027

Forensic Technologies: New and Growing Markets – Biotechnology, Healthcare Industries

The Forensic Technologies: New and Growing Markets Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare Markets.

Report Includes

  • An overview of new and growing markets for forensic technologies
  • Analyses of market trends in forensic technologies, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Information on all areas of the forensics market, including identification of current and future technologies, products, market segments and end markets, and regulatory agencies
  • Information on major patents filed
  • Information on participating companies in light of technological strengths and weaknesses, relative market shares, marketing strengths, and innovative marketing practices

In preparing this report, an overall study of the crime laboratory segment of the U.S. forensic science market was undertaken. Related areas provided key information; as newer areas such as computer forensics make up a growing share of the total forensics business. All areas of the forensics market are addressed including identification of current and future technologies, products, market segments/end markets, and government and regulatory agencies. Participating companies are discussed in light of technological strengths and weaknesses, relative market share, marketing strengths and innovative marketing practices.

Read more and order at Forensic Technologies: New and Growing Markets

Innovations in Biocomposites – High-Tech Materials TOE – Biomaterials, Biotechnology, Healthcare Industries

The Innovations in Biocomposites – High-Tech Materials TOE Report has been published. It provides updated in 2018 year analysis of industries from Biomaterials, Biotechnology, Healthcare Markets.

Composites comprising a biological element or derived from bio-based sources, commonly known as biocomposites, have gained considerable interest over the past decade across industries. In commercial biocomposites, reinforcement agents such as plant fibers and regenerated cellulose fibers are commonly used, while the matrices of the composite materials include polymers derived from renewable sources, and even virgin or recycled thermoplastics. The automotive industry has the highest adoption potential for biocomposites followed by marine and construction industries.

The High-Tech Materials TechVision Opportunity Engine (TOE) provides intelligence on technologies, products, processes, applications, and strategic insights on various materials across industries. Some material technologies include lightweight materials, bio-based materials, ceramics, smart materials, fibers, nanomaterials, responsive materials, polymers, woven and non woven materials, polymers and plastics and packaging materials.

The Materials and Coatings cluster tracks research and innovation trends and developments across specialty chemicals, plastics, polymers, chemicals, bio-chemicals, metals, coatings, thinfilms, surface treatments, composites, alloys, oil and gas, fuel additives, fibers, and several other related technologies and its impact and application across industries.

Read more and order at Innovations in Biocomposites – High-Tech Materials TOE

Global Protein Labelling Market – Growth, Trends and Forecasts (2017 – 2022) – Biotechnology, Healthcare, Proteomics Industries

The Global Protein Labelling Market – Growth, Trends and Forecasts (2017 – 2022) Report has been published. It provides updated in 2018 year analysis of industries from Biotechnology, Healthcare, Proteomics Markets.

The global protein labeling market is estimated to be USD XX billion in 2017 and is expected to reach USD XX billion by 2022, registering a healthy CAGR of XX%, during 2017-2022 (forecast period).

Protein labeling is the application of appropriate molecular labels to purify or detect the labelled protein and its binding partners. It plays an important role in proteomics, which is the detailed analysis of proteins. Further, the detailed analysis generates scope to develop new drugs, which are expected to target the disease pathways more efficiently. In addition, it has led to the development of novel drugs for cancer, cardiovascular, and neurodegenerative diseases, which strengthened the market, in recent years.

The increasing research in proteomics and the expansion of investments in R&D are the major factors accelerating the global market. However, lack of skilled professionals in this field is hindering the market growth. The improving economic performance of emerging markets has opened new opportunities for the companies operating in this field.

The global protein labeling market, by product type, is segmented into reagents & kits, services and others. By application, the market is segmented into cell-based assays, immunological techniques, fluorescence microscopy, protein microarrays and mass spectrometry. Based on the labeling method, the market is segmented into in-vitro labeling, in-vivo labeling and bio-orthogonal labeling. The In-Vitro labeling segment is further divided into enzymatic, dye-based labeling and others. The In-Vivo labeling segment is divided into photo-reactive and radioactive labeling.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America. These regions are further segmented into countries in their respective regions.

The major players in this market are:

Merck KGaA
Thermo Fisher Scientific Inc
Kaneka Corporation
F. Hoffman-La Roche AG

A detailed analysis of these companies is provided in the report.

Key Deliverables

Market analysis, with region-specific assessments and competition analysis on a global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, growing prospective opportunities, and identification of key companies that can influence the market.

Extensively researched competitive landscape section with profiles of major companies, along with their market share.

Identification and analysis of the macro and micro factors that affect the market on both, global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-range of knowledge and insights about the major players in the industry and the key strategies adopted by them to sustain and grow in the studied market
Insights on the major countries/regions where the industry is growing, and identify the regions that are still untapped.

Read more and order at Global Protein Labelling Market – Growth, Trends and Forecasts (2017 – 2022)

Receptors of Cell Adhesion and Cellular Recognition, Vol 3. Biomembranes. A Multi-Volume Treatise – Biomaterials, Biotechnology, Healthcare Industries

The Receptors of Cell Adhesion and Cellular Recognition, Vol 3. Biomembranes. A Multi-Volume Treatise Report has been published. It provides updated in 2018 year analysis of industries from Biomaterials, Biotechnology, Healthcare Markets.

Volume 3 of Biomembranes covers receptors of cell adhesion and cellular recognition. Proteins in the plasma membrane of cells are heavily involved in processes of cell adhesion, but such proteins were not actually isolated and characterized until the mid-1970s. Since then, application of the methods of molecular biology has led to the recognition of four major classes of cell adhesion molecule (CAMs), the immunoglobulin super family, the cadherins, the integrins, and the selecting. A convenient system in which to study the importance of cell adhesion is in blood platelets where aggregation eventually leads to thrombus formation in a process involving a range of surface glycoproteins. Interaction with the extracellular matrix is exemplified by CD44, the receptor for hyaluronan, and a complex carbohydrate that is a major component of the extracellular matrix surrounding migrating and proliferating cells. Membrane-associated mucins have a variety of effects on cell adhesion. The super family of immunoglobulin related proteins also include the T cell receptors and the major histocompatibility complex (MHC), which, together with the receptors for immunoglobulins (the Fc receptors), are of fundamental importance in the processes of immunity. Volume 3 of Biomembranes explores the structures and functions of the molecules involved in these important functions of the cell.

Read more and order at Receptors of Cell Adhesion and Cellular Recognition, Vol 3. Biomembranes. A Multi-Volume Treatise